Table 2 |
||||||
| GI50, TGI and LC50 (μg/mL) for EAD and Dox | ||||||
| EAD | Dox | |||||
| Cancer cell lines | GI50 | TGI | LC50 | GI50 | TGI | LC50 |
| U251 (glioma) | 83.47 | 5.07 | 23.45 | |||
| UACC-62 (melanoma) | > 100 | 0.06 | 0.86 | |||
| MCF7 (breast) | 11.10 | > 100 | 0.14 | 24.52 | ||
| NCI/ADR-RES (ovarian resistance) | 1.95 | 1.74 | 23.92 | |||
| 786-0 (renal) | > 100 | 0.22 | 1.51 | |||
| NCI-H460 (lung) | 0.03 | > 100 | 0.05 | |||
| OVCAR-3 (ovarian) | 6.38 | 0.30 | 1.72 | |||
| HT29 (colon) | 0.10 | 4.10 | > 100 | 2.12 | 7.31 | 20.86 |
| K-562 (leukemia) | 31.13 | 0.90 | ||||
| Vero | 1.40 | 11.36 | ||||
EAD (crude methanol extract); dox (doxorubicin); GI50 (growth inhibitory activity); TGI (cytostatic activity); LC50 (cytotoxic activity); IC50 >100 (μg/mL) was considered not active.
Formagio et al. BMC Complementary and Alternative Medicine 2013 13:14 doi:10.1186/1472-6882-13-14
